Depressive symptoms · treatment‐resistant depression in adults
2 findings from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in response (≥50% reduction in MADRS score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Remission ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
Lithium probably leads to lower efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score… compared with olanzapine (moderate certainty).
1 finding from 1 review
Efficacy: response (continuous) CGI severity score at end of study · acute mania
1 finding from 1 review
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with olanzapine (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium may leads to higher acceptability: total withdrawals compared with olanzapine (low certainty).
1 finding from 1 review
Adverse events · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Adults (aged 18 and over) with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate leads to lower adverse events ‐ Sedation At 3‐12 weeks (secondary tolerability… compared with olanzapine (high certainty).
1 finding from 1 review
Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review
Dropout · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause At 3‐12 weeks (secondary acceptability… compared with olanzapine (high certainty).
1 finding from 1 review